The FT named Lars Jorgensen, chairman of Novo Nordisk, a weight-loss company, as its Person of the Year
Kyiv • UNN
Lars Jorgensen, CEO of Novo Nordisk, has been named the Financial Times Person of the Year for his leadership in developing diabetes drugs with significant weight loss effects, which allowed the company to become the most valuable in Europe in 2023.
The British Financial Times newspaper recognized Lars Jorgensen, the head of a Danish company that created a of a Danish company that created a drug for the treatment of diabetes with a significant weight loss effect, UNN reports .
Jorgensen is a pioneer of private innovations that can impact not only healthcare, but also society, public funding, and our relationship with food,
Details
The publication emphasizes the role of Jorgensen's role in implementing the model of "slow, persistent, but transformative innovation and transformative innovation," drawing attention to his restraint despite his status as of the company's CEO.
For reference
Novo Nordisk. is the developer of Ozempic and Wegovy. Ozempic is a drug that is is used to treat type 2 diabetes. One of its side effects is is weight loss. At the same time, many people without diabetes use it not for "diabetic" purposes, but rather to lose weight.
У In 2023, Novo Nordisk became the most valuable company in Europe the most valuable company in Europe. According to analysts at Barclays, Wegovy's sales will reach $4.2 billion this year and $7.3 billion in 2024. Ozempic's sales are projected to grow to $16.5 billion next year.
Recall
Taylor Swift was awarded the title "Person of the Year 2023"by Time magazine, and this title made her feel proud, happy and fulfilled
